There is an artificial intelligence boom happening in the life sciences sector, says Guido Lanza, president and CEO of AI biotech company Numerate Inc., but pharma and biotech are playing catch-up to other industries where this technological advancement is already being successfully applied.
Numerate has been using an algorithm-centric process to drive its preclinical drug discovery and development decisions for several years –...